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DISCUSSION
Dr Richard Powell (Lebanon, NH). The Guidant 2500 data
were recently presented, and one of the conclusions of that study
was that the low-volume operators had equivalent results with the
high-volume operators following their prescribed training course.
I was just wondering if you would comment on that, especially in
light of your study, which shows that, if anything, more cases may
be required.
Dr Cao. I have no real comment on that. This is a single-
center with independent results. It’s striking to see how the first
interval carries a higher risk with a protective device. In our
experience, the learning curve was still a crucial aspect of our
results.
Dr Marc Bosiers (Dendermonde, Belgium). All 18 observed
minor strokes occurred in the postprocedural phase. Was any
correlation observed between the selected stent types and the
number of observed events? What could be the reasoning?
In the EVA-3S study, the controlled randomized trial com-
paring CAS vs CEA in France, which is going to be published, CEA
turns out to be superior over CAS. Taking into account this
publication, I would like to hear your comment on the required
study credentials: an experience of minimally 50 to 100 CEA
procedures is required, while participating centers only need 10 to
15 documented CAS cases.
Dr Cao. Regarding the stent configuration, we have not
enough numbers to evaluate the difference; also, many events
occurred during the unprotected phase. Consequently, we would
need a very large sample size.
As to the learning curve, I completely agree with you. The
main problem of all randomized trials, including the technical
aspect, is that centers with an incomplete learning curve can be
recruited. So, probably, to fully evaluate the results of different
techniques in randomized trials, we should be careful to select
centers with adequate track records.
Dr Munier Nazzal (Toledo, Ohio). I have one question re-
garding the catheter experience. Did you look at catheter experi-
ence in other vessels? Because the operators might be new in the
carotid, but they do other procedures, like renal, which might be
more difficult even sometimes than carotid.
Dr Cao. Let me first specify that our cases were done in the
operating room with a fixed imaging system during the last 6
months. Previously a digitalized mobile system was used, with a
team made of a radiologist with a large experience of catheteriza-
tion and a vascular surgeon. I think that the background of the
team was adequate.
Dr Robert Hobson (Newark, NJ). Dr Cao, I appreciated
your presentation. It’s what we have come to expect from the
University of Perugia.
My question has to do with your calculation of a learning
curve. The CREST investigators here in North America and our
biostatistical associates have been working on a similar project. It’s
particularly difficult to perform these analyses when you have a low
number of end points, as you do, and the excellence of your work
confirms that.
However, I noticed that you did not recommend a number of
cases that you think is appropriate for a vascular surgeon to then
proceed independently with carotid artery stenting. The Interven-
tional Management Committee of CREST has put this figure at
about 30 cases. But if you look at the biostatistics of this question,
it may be as low as 15 cases, which reinforces Dr Powell’s com-
ments about Guidant’s ARCHeR data in that “experienced” inter-
ventionalists did as well as more experienced clinicians. If you
could please review your method of analysis on the learning curve,
perhaps you can then recommend an appropriate number of cases.
Finally, like Dr Bosiers, do you have any insight on the results
of the EVA-3S trial, which apparently demonstrated a benefit for
endarterectomy over stenting.
Dr Cao. In our study we included all the cases of carotid
stenting, trying to localize the time of occurrence of the compli-
cation. I think this is quite crucial, because many other reports, in
my opinion, didn’t focus on this topic.
With regard to the caseload, I think we cannot generalize our
results. A person can be trained in different ways, with a proctor,
going to other centers, and so on. For sure, according to our
experience, the previously suggested number seems quite low to
assure safety of carotid stenting.
Dr John Ricotta (Stony Brook, NY). Dr Cao, excellent pre-
sentation, and I want to thank you for starting me on my learning
curve several months ago. I have two questions for you.
It seemed tome that in the second period, you liberalized your
indications for stenting. You were stenting people with less periph-
eral vascular disease and less coronary disease. I wonder if you
would comment on whether you think that influenced the out-
come of your patients. Do you think that the patient groups were
similar, or do you think that as you liberalized your indication for
stenting, you were actually doing stenting on a safer group of
patients?
I also have a comment, similar to what other people have said:
if we’re going to start on a learning curve, somehow you have to
get to 200 cases. What suggestions do you have for us to select
patients between number 10 and number 200?
Dr Cao. I was aware that by presenting 200 cases as a learning
curve, most of the vascular surgeons would shoot me, because it
makes the starting experience very difficult. I would say, again, that
these results are not intended to be guidelines. I would suggest to
start with patients with easy-access vessels, low-risk patients, pos-
sibly with a team approach including different specialties.
Regarding the possible selection bias of the results, we have
pointed out that this is not a randomized study. With multivariable
analysis, we showed that patient characteristics were not predictors
of complications.
Dr Marc Schermerhorn (Boston, Mass). In your analysis, age
was a weak predictor of outcome, but it looked like you were
analyzing it as a continuous variable. Did you look at it as a dichoto-
mous variable? What were the stroke rates above and below 80?
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DrCao.We tended to exclude symptomatic patients above 80
years of age. That is why we had to use age as a continuous variable;
otherwise, we couldn’t have any results.
Dr Jean Becquemin (Creteil, France). It cannot be denied
that the learning curve is very important in this topic of carotid
stenting.
Previous discussants of your paper and yourself have quoted
the French randomized study EVA-3S, comparing CEA and CAS
in symptomatic patients. The final data have not been published
yet, so I am not allowed to give the raw figures. But being a
member of the organizing committee of the study, I can tell you
that most of the complications in the CAS group did not happen in
low-volume centers, but they happened in the group of practitio-
ners who had the high-volume cases. So the problem of learning
curve is important, but it’s not all. Since in the second part of your
study you enlarged the indications to asymptomatic patients, the
improved results may reflect the fact that you have treated less
severe and, thus, less dangerous lesions.
Dr Cao. I have no reply. I agree with you.
INVITED COMMENTARY
Marc Bosiers, MD, Dendermonde, Belgium
After reviewing their 627 carotid angioplasty and stenting
(CAS) procedures performed over the last 6 years, the vascular
team fromPerugia, directed by a vascular surgeon, determined that
the caseload necessary to be able to perform CAS with similar
outcomes as carotid endarterectomy (CEA) was 195 cases. Al-
though this figure seems high, I agree that the minimum number
of performed procedures, which ranges from 10 to 30, to be
allowed to perform CAS independently that is currently recom-
mended by different societies, hospitals, and study recruiters is far
too low. In our center we found that we needed approximately 75
cases to lower our complication rate to an ethically acceptable level.
Once this level of expertise was achieved, we observed a similar
switch from CEA to CAS, which was mainly driven by the patient
demands for a minimally invasive procedure with a similar outcome
as surgery.1
Interestingly in the Perugia series, just as in other high-volume
centers, the same shift of the timing of complications from intra-
procedural to postprocedural was observed.2 During CEA, the
emboligenic plaque is removed, but in CAS the plaque material is
compressed into the vessel wall and contained by the stent, which
remains the only protection against embolization after the proce-
dure. As our group has recently found,3 a significant correlation
exists between more postprocedural events and a larger free cell
area of the stent, especially in symptomatic patients.
In this light, one can argue that the recently published data
from the randomized Endarterectomy Versus Angioplasty in Pa-
tients With Severe Symptomatic Carotid Stenosis (EVA-3S) and
Stent Protected Percutaneous Angioplasty of the Carotid vs. End-
arterectomy (SPACE) trials that failed to demonstrate equivalency
for CAS vs CEA needs an in-depth subanalysis of the learning curve
experience of the centers and types of stent (free cell area) that
potentially caused more adverse events in the CAS group.
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